Overview

SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Status:
Recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

This is an open-label, single center, non-randomized, phase I trial to evaluate safety and efficacy of using the combination treatment of SHR-1210 with Paclitaxel-albumin and gemcitabine of metastatic PDAC.

Phase:

N/A

Details

Lead Sponsor:

RenJi Hospital

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel